Effect of bone marrow mesenchymal stem cells on experimental pulmonary arterial hypertension

Zhang,Zhao-Hua; Lu,Yan; Luan,Yun; Zhao,Jing-Jie

doi:10.3892/etm.2012.691

Effect of bone marrow mesenchymal stem cells on experimental pulmonary arterial hypertension

Authors:
- Zhao-Hua Zhang
- Yan Lu
- Yun Luan
- Jing-Jie Zhao
View Affiliations

Affiliations: Department of Pediatrics, The Second Hospital of Shandong University, Jinan, P.R. China, Department of Pathology, Hospital of Beijing University of Aeronautics and Astronautics, Beijing, P.R. China, Central Research Laboratory, The Second Hospital of Shandong University, Jinan, P.R. China, Clinical Molecular Biology Laboratory, The Second Hospital of Shandong University, Jinan, P.R. China
Published online on: August 31, 2012 https://doi.org/10.3892/etm.2012.691
Pages: 839-843

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the effect of bone marrow mesenchymal stem cell (BMSC) transp1antation on lung and heart damage in a rat model of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH). The animals were randomly divided into 3 groups: control, PAH and BMSC implantation groups. Structural changes in the pulmonary vascular wall, such as the pulmonary artery lumen area (VA) and vascular area (TAA) were measured by hematoxylin and eosin (H&E) staining, and the hemodynamics were detected by echocardiography. Two weeks post-operation, our results demonstrated that sublingual vein injection of BMSCs significantly attenuated the pulmonary vascular structural and hemodynamic changes caused by pulmonary arterial hypertension. The mechanism may be executed via paracrine effects.

View Figures

View References

1	Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, Stenmark KR, Thistlethwaite PA, Weissmann N, Yuan JX and Weir EK: Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol. 54:S20–S31. 2009. View Article : Google Scholar : PubMed/NCBI
2	Kanki-Horimoto S, Horimoto H, Mieno S, Kishida K, Watanabe F, Furuya E and Katsumata T: Implantation of mesenchymal stem cells overexpressing endothelial nitric oxide synthases improves right ventricular impairments caused by pulmonary hypertension. Circulation. 114:I181–I185. 2006.
3	Baber SR, Deng W, Master RG, Bunnell BA, Taylor BK, Murthy SN, Hyman AL and Kadowitz PJ: Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol. 292:H1120–H1128. 2007. View Article : Google Scholar
4	Patel KM, Crisostomo P, Lahm T, Markel T, Herring C, Wang M, Meldrum KK, Lillemoe KD and Meldrum DR: Mesenchymal stem cells attenuate hypoxic pulmonary vasoconstriction by a paracrine mechanism. J Surg Res. 143:281–285. 2007. View Article : Google Scholar : PubMed/NCBI
5	Miura M, Hirose M, Endoh H, Wakayama Y, Sugai Y, Nakano M, Fukuda K, Shindoh C, Shirato K and Shimokawa H: Acceleration of Ca²⁺ waves in monocrotaline-induced right ventricular hypertrophy in the rat. Circ J. 75:1343–1349. 2011.
6	Wang CH, Cherng WJ, Yang NI, Kuo LT, Hsu CM, Yeh HI, Lan YJ, Yeh CH and Stanford WL: Late-outgrowth endothelial cells attenuate intimal hyperplasia contributed by mesenchymal stem cells after vascular injury. Arterioscler Thromb Vasc Biol. 28:54–60. 2008. View Article : Google Scholar : PubMed/NCBI
7	Westerweel PE and Verhaar MC: Directing myogenic mesenchymal stem cell differentiation. Circ Res. 103:560–561. 2008. View Article : Google Scholar : PubMed/NCBI
8	Gehrke I, Gandhirajan RK, Poll-Wolbeck SJ, Hallek M and Kreuzer KA: Bone marrow stromal cell-derived vascular endothelial growth factor (VEGF) rather than chronic lymphocytic leukemia (CLL) cell-derived VEGF is essential for the apoptotic resistance of cultured CLL cells. Mol Med. 17:619–627. 2011. View Article : Google Scholar
9	Crosswhite P and Sun Z: Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension. J Hypertens. 28:201–212. 2010. View Article : Google Scholar : PubMed/NCBI
10	Gao J, Dennis JE, Muzic RF, Lundberg M and Caplan AI: The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs. 169:12–20. 2001. View Article : Google Scholar : PubMed/NCBI
11	Nagaya N, Fujii T, Iwase T, Ohgushi H, Itoh T, Uematsu M, Yamagishi M, Mori H, Kangawa K and Kitamura S: Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am J Physiol Heart Circ Physiol. 287:H2670–H2676. 2004. View Article : Google Scholar
12	Choudhary M, Zhang X, Stojkovic P, Hyslop L, Anyfantis G, Herbert M, Murdoch AP, Stojkovic M and Lako M: Putative role of hyaluronan and its related genes, HAS2 and RHAMM, in human early preimplantation embryogenesis and embryonic stem cell characterization. Stem Cells. 25:3045–3057. 2007. View Article : Google Scholar : PubMed/NCBI
13	Luan Y, Liu XC, Zhang GW, Shi RF, Zhao XB, Zhao CH, Liu TJ, Lü F, Yang Q and He GW: Mid-term effect of stem cells combined with transmyocardial degradable stent on swine model of acute myocardial infarction. Coron Artery Dis. 21:233–243. 2010. View Article : Google Scholar : PubMed/NCBI
14	Wang Y, Liu XC, Zhang GW, Zhao J, Zhang JM, Shi RF, Huang YZ, Zhao CH, Liu TJ, Song CX, Lü F, Yang Q and He GW: A new transmyocardial degradable stent combined with growth factor, heparin, and stem cells in acute myocardial infarction. Cardiovasc Res. 84:461–469. 2009. View Article : Google Scholar : PubMed/NCBI
15	Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA and Verfaillie CM: Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 418:41–49. 2002. View Article : Google Scholar : PubMed/NCBI
16	Oswald J, Boxberger S, Jørgensen B, Feldmann S, Ehninger G, Bornhäuser M and Werner C: Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells. 22:377–384. 2004. View Article : Google Scholar : PubMed/NCBI
17	Luan Y, Zhang ZH, Wei DE, Zhao JJ, Kong F, Cheng GH and Wang YB: Implantation of mesenchymal stem cells improves right ventricular impairments caused by experimental pulmonary hypertension. Am J Med Sci. 343:402–406. 2012. View Article : Google Scholar : PubMed/NCBI
18	Frid MG, Brunetti JA, Burke DL, Carpenter TC, Davie NJ, Reeves JT, Roedersheimer MT, van Rooijen N and Stenmark KR: Hypoxia-induced pulmonary vascular remodeling requires recruitment of circulating mesenchymal precursors of a monocyte/macrophage lineage. Am J Pathol. 168:659–669. 2006. View Article : Google Scholar
19	Rochefort GY, Vaudin P, Bonnet N, Pages JC, Domenech J, Charbord P and Eder V: Influence of hypoxia on the domiciliation of mesenchymal stem cells after infusion into rats: possibilities of targeting pulmonary artery remodeling via cells therapies? Respir Res. 6:1252005. View Article : Google Scholar : PubMed/NCBI
20	Tang J, Xie Q, Pan G, Wang J and Wang M: Mesenchymal stem cells participate in angiogenesis and improve heart function in rat model of myocardial ischemia with reperfusion. Eur J Cardiothorac Surg. 30:353–361. 2006. View Article : Google Scholar : PubMed/NCBI
21	Jiang S, Kh Haider H, Ahmed RP, Idris NM, Salim A and Ashraf M: Transcriptional profiling of young and old mesenchymal stem cells in response to oxygen deprivation and reparability of the infarcted myocardium. J Mol Cell Cardiol. 44:582–596. 2008. View Article : Google Scholar : PubMed/NCBI
22	Al-Khaldi A, Al-Sabti H, Galipeau J and Lachapelle K: Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg. 75:204–209. 2003. View Article : Google Scholar : PubMed/NCBI
23	Guo Y, He J, Wu J, Yang L, Dai S, Tan X and Liang L: Locally overexpressing hepatocyte growth factor prevents post-ischemic heart failure by inhibition of apoptosis via calcineurin-mediated pathway and angiogenesis. Arch Med Res. 39:179–188. 2008. View Article : Google Scholar